DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993
(ibrutinib) Capsules. In the overall assessment, discuss whether the data warrants further detailed assessment, labeling changes and/or other communication about these adverse events. Continue the study for a period of four years from the date of final pr...